2018年度発表論文等一覧

原著論文－英文

1. Ando Y, Iwasa S, Takahashi S, Saka H, Kakizume T, Natsume K, Suenaga N, Quadt C, Yamada Y.
   Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.
   Cancer Sci 110:1021-1031, 2018. (IF: 6.716)
2. Shida H, Naito T, Shibata K, Yamada Y, Kawakami J.
   LC-MS/MS method for denosumab quantitation in human serum with rapid protein digestion using immobilized trypsin.
   Bioanalysis 10:1501-1510, 2018. (IF: 2.371)
3. Tanaka H, Naito T, Sato H, Hiraide T, Yamada Y, Kawakami J.
   Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
   Eur J Clin Pharmacol 74:1461-1469, 2018. (IF: 3.263)
4. Roy R, Kandimalla R, Sonohara F, Koike M, Kodera Y, Takahashi N, Yamada Y, Goel A.
   A comprehensive methylation signature identifies lymph node metastasis in esophageal squamous cell carcinoma.
   Int J Cancer 144:1160-1169, 2019. (IF: 7.396)
5. Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW.
   Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19:660-671, 2018. (IF: 41.316)
6. Shigeyasu K, Okugawa Y, Toden S, Miyoshi J, Toiyama Y, Nagasaka T, Takahashi N, Kusunoki M, Takayama T, Yamada Y, Fujiwara T, Chen L, Goel A.
   AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. JCI Insight 3:99976, 2018. (IF: 8.315)
7. Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y.
   Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. Br J Radiol 91:20180259, 2018. (IF: 2.196)
8. Okita A, Takahashi S, Ouchi K, Inoue M, Watanabe M, Endo M, Honda H, Yamada Y, Ishioka C.
   Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget 9:18698-18711, 2018. (IF: 3.765)
9. Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C.
   S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial. Ann Oncol 29:624-631, 2018. (IF: 32.976)
10. Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra CR, Kopetz S, Wang X, Goel A.
    Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer. Clin Cancer Res 24:3867-3877, 2018. (IF: 12.531)
11. Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N.
    A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol 23:466-472, 2018. (IF: 3.402)
12. Sonohara F, Gao F, Iwata N, Kanda M, Koike M, Takahashi N, Yamada Y, Kodera Y, Wang X, Goel A.
    Genome-wide discovery of a novel gene-expression signature for the identification of lymph node metastasis in esophageal squamous cell carcinoma. Ann Surg 269:879-886, 2019. (IF: 10.13)
13. Akiyoshi K, Hamaguchi T, Yoshimura K, Takahashi N, Honma Y, Iwasa S, Takashima A, Kato K, Yamada Y, Onodera H, Takeshita S, Yasui H, Sakai G, Akatsuka S, Ogawa K, Horita Y, Nagai Y, Shimada Y.
    A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
    Clin Colorectal Cancer 17: e83-e89, 2018. (IF: 4.481)
14. Sudo K, Kato K, Kuwabara H, Sasaki Y, Takahashi N, Shoji H, Iwasa S, Honma Y, Okita NT, Takashima A, Hamaguchi T, Yamada Y, Ito Y, Itami J, Fukuda T, Tobinai K, Boku N.
    Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma.
    Oncology 94:47-54, 2018. (IF: 2.642)
15. Doi T, Hewes B, Kakizume T, Tajima T, Ishikawa N, Yamada Y.
    Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
    Cancer Sci 109:193-198, 2018. (IF: 6.716)
16. Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A.
    Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
    Gastric Cancer 21:429-438, 2018. (IF: 7.370)

著書・総説

総説論文・和文

1. 山田康秀
   わが国におけるがんゲノム医療の展望.
   外科　（南江堂）80:1193-1199, 2018